ReviewTranslational psychiatry2017
Experimental medication treatment approaches for depression.
Review in Translational psychiatry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 77 citations in OpenAlex.
- A randomized, multicenter trial assessing the effects of rapastinel compared to ketamine, alprazolam, and placebo on simulated driving performance.Clinical and translational science · 2022Trial
- The Antidiabetic Metformin as an Adjunct to Antidepressants in Patients with Major Depressive Disorder: A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2020Trial
- A phase 2, double-blind, placebo-controlled study of NSI-189 phosphate, a neurogenic compound, among outpatients with major depressive disorder.Molecular psychiatry · 2020Trial
- Effects of the Probiotics Lactobacillus rhamnosus DM163 and Lactobacillus delbrueckii DPUL-F36 on Anxiety-Related and Emotional Behaviors in Male Wistar Rats Under an Altered Light-Dark Cycle.Brain and behavior · 2025Article
- The involvement of KTranslational psychiatry · 2024Review
- Comparison between Substance P and Calcitonin Gene-Related Peptide and Their Receptors in Colorectal Adenocarcinoma.Journal of clinical medicine · 2024Article
- Preclinical models of treatment-resistant depression: challenges and perspectives.Pharmacological reports : PR · 2023Review
- Cytokine and Reward Circuitry Relationships in Treatment-Resistant Depression.Biological psychiatry global open science · 2022Article
- Major depressive disorder: Validated treatments and future challenges.World journal of clinical cases · 2021Review
- Exercise mimetics: harnessing the therapeutic effects of physical activity.Nature reviews. Drug discovery · 2021Review
- Significant reduction in depressive symptoms among patients with moderately-severe to severe depressive symptoms after participation in a therapist-supported, evidence-based mobile health program delivered via a smartphone app.Internet interventions · 2021Article
- Advances in novel molecular targets for antidepressants.Progress in neuro-psychopharmacology & biological psychiatry · 2021Review
- Influence of the endocannabinoid system on the antidepressant activity of bupropion and moclobemide in the behavioural tests in mice.Pharmacological reports : PR · 2020Article
- Antidepressant Effects and Mechanisms of Group II mGlu Receptor-Specific Negative Allosteric Modulators.Neuron · 2020Article
- Vasopressin Surrogate Marker Copeptin as a Potential Novel Endocrine Biomarker for Antidepressant Treatment Response in Major Depression: A Pilot Study.Frontiers in psychiatry · 2020Article
- Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression.Journal of affective disorders · 2020Article
- Allostatic load in the association of depressive symptoms with incident coronary heart disease: The Jackson Heart Study.Psychoneuroendocrinology · 2019Article
- α-Fluorination of carbonyls with nucleophilic fluorine.Nature chemistry · 2019Article
- Depression as a Neuroendocrine Disorder: Emerging Neuropsychopharmacological Approaches beyond Monoamines.Advances in pharmacological sciences · 2019Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Depression is one of the most common psychiatric conditions. Symptoms can lead to significant disability, which result in impairments in overall quality of life. Though there are many approved antidepressant treatments for depression-including selective serotonin reuptake inhibitors, tricyclic antidepressants and monoamine oxidase inhibitors-about a third of patients do not respond to these medications. Therefore, it is imperative for drug discovery to continue towards the development of novel and rapidly acting compounds, especially for patients with treatment-resistant depression. After a brief review of the efficacy of approved antidepressant therapies, we will discuss experimental medication treatments for depression. Specifically, we examine novel medications that are thought to primarily modulate the glutamatergic, cholinergic and opioid systems to achieve antidepressant efficacy. We also give examples of anti-inflammatories, neurokinin-1 modulators, vasopressin antagonists and neurogenesis enhancers that may have a therapeutic role in treatment-resistant depression. The current pipeline of antidepressant treatments is shifting towards medications with novel mechanisms, which may lead to important, life-changing discoveries for patients with severe disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.